

# Clinical Trials of Texas, Inc.

Dedicated to the advancement of new medical therapies.

## Curriculum Vitae

### Edward Reed Sargent, MD, FACP

7940 Floyd Curl, Ste. 1050  
San Antonio, Texas 78229

8401 Datapoint Drive, Ste. 401  
San Antonio, Texas 78229

#### EDUCATION

- 1976 Bachelors of Arts Degree: Magna Cum Laude, Phi Beta Kappa, University of Missouri, Columbia, Missouri  
1980 Doctoral of Medicine: Cum Laude, University of Missouri, Columbia Missouri  
1980-1981 Straight Medical Internship, University of Texas Health Science Center at San Antonio, San Antonio, Texas  
1981-1982 Texas Jr. Assistant Resident in Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas  
1982-1983 Senior Assistant Resident in Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas

#### CERTIFICATIONS AND TRAINING

- 2007 Good Clinical Practices: Practical Application and Implementation  
2003 Fellow of the American College of Physicians  
1983 Board Certified by the American Board of Internal Medicine

#### LICENSURE

- 1981 Texas Board of Medical Examiners, # G0059

#### PROFESSIONAL EXPERIENCE

- 1998-Present Co-Owner, San Antonio Preventive & Diagnostic Medicine, P.A., San Antonio, Texas  
1983-1997 Partner, The Diagnostic Clinic of San Antonio, P.A.

#### RESEARCH AFFILIATION

- 2004-Present Principal Investigator/Sub-Investigator, Clinical Trials of Texas, Inc., San Antonio, TX

#### PROFESSIONAL AFFILIATIONS

- Fellow American College of Physicians  
Bexar County Medical Society  
Texas Medical Society  
American Academy of Pharmaceutical Physicians, 2000-2002

#### HOSPITAL STAFF

- St. Luke's Baptist Hospital  
Southwest Texas Methodist Hospital  
Methodist Specialty and Transplant Hospital

## APPOINTMENTS

2004-2006 Medical Executive, St. Luke's Baptist Hospital  
2003-2004 Chief of Staff St. Luke's Baptist Hospital  
2001-Present President SAPDM  
1998-2001 Vice President SAPDM  
1999-2002 Medical Director, Clinical Research, SAPDM  
1999-Present Clinical Professor UTHSCSA  
1996-1998 Medical Director, Skilled Nursing Unit, Community Hospital  
1996-1997 Board Member PASA  
1990-1999 Clinical Associate Professor UTHSCSA  
1986-1990 Clinical Assistant Professor UTHSCSA  
1984-1985 Clinical Instructor UTHSCSA, University of Texas Health Science Center  
1986 Medical Records Committee, S.W. Texas Methodist Hospital  
1988 Chairman, Department of Medicine, St. Luke's Lutheran Hospital  
1987-1988 Utilization Review Physician, Walden Oaks  
1987-1988 Medical Director, Four Seasons of the Village Nursing Home  
1987-1988 Board of Advisors, Independence Hill Retirement Home  
1987-1989 Utilization Review Committee, Pacificare of Texas

Chairman, Utilization Review Committee, St. Luke's Lutheran Hospital  
Medical Director, ABC Home Health

## AWARDS

1999 ACP Community-Based Teaching Recognition Award

## CLINICAL TRIALS EXPERIENCE

2007-Present; A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX in Subjects with Uncomplicated Acute Influenza

2007-Present; A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-design, Phase 2 Trial of Oral XXXXX Administered to Patients with Irritable Bowel Syndrome with Constipation

2007-Present; A Randomized-Withdrawal Phase III Study Evaluating the Safety and Efficacy of XXXXX Extended-Release (ER) in Subjects with Painful Diabetic Peripheral Neuropathy (DPN)

2007-Present; A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXXXX (XXXXX) as Mono-therapy in the Treatment of Elderly Patients with Major Depressive Disorder (SAPPHIRE STUDY)

2007-Present; A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXXXX (XXXXX) as Mono-therapy in the Treatment of Elderly Patients with Generalised Anxiety Disorder (CHROMIUM STUDY)

2007-Present; A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXXXX as Mono-therapy in the Treatment of Adult Patients with Major Depressive Disorder

2007-Present; A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of XXXXX (XXXXX) Compared with Placebo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a Selective Serotonin Reuptake Inhibitor or Serotonin-Norepinephrine Reuptake Inhibitor Alone or in Combination with a Benzodiazepine

2007-Present; Double-Blind Follow-On Safety Study of XXXXX in Subjects Who Have Completed Participation in XXXXX Protocol XXXXX or XXXXX Protocol XXXXX

2007-Present; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of XXXXX When Used in Combination with XXXXX in Subjects with Type 2 Diabetes

2006-Present; A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of XXXXX in Subjects Requiring NSAID Treatment

2006-Present; A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of XXXXX (XXXXX) as Monotherapy in the Maintenance Treatment of Patients with Generalized Anxiety Disorder Following an Open-Label Stabilisation Period (PLATINUM STUDY)

2006-Present; A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of XXXXX (XXXXX) in Subjects with Type 2 Diabetes

2006-2007; A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXXXX Combination Therapy to XXXXX Monotherapy in Subjects with Mixed Dyslipidemia

2006-2007; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of XXXXX When Used in Combination with XXXXX in Subjects with Type 2 Diabetes

2005-2006; A 12-Week, Multicenter, Double-Blind, Randomized Efficacy and Safety Study of XXXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome

2004-2005; A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of XXXXX in Elderly Subjects with Major Depressive Disorder

2004-2005; A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXX for the Treatment of Painful Diabetic Neuropathy

2004-2005; A 24-Week Randomized, Double-Blind, Double-Dummy, Multicenter Study to Compare the Efficacy of XXXXX and XXXXX (8mg OD) in Subjects with Type 2 Diabetes Mellitus

2003-2004; A Phase 3, Randomized, Double-Blind, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of an Investigational Drug in Combination with XXXXX Compared to XXXXX in Combination with XXXXX in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

2002-2002; Phase IIIb, A Prospective, Randomized, Double-Blind, Parallel-Group, Study Comparing the Antiproteinuric Effects of XXXXX Tablets (XXXXX) and XXXXX When Each are Added to XXXXX 100mg in Treating Diabetic Hypertensive Subjects with Proteinuria

2002-2002; Phase III, A Randomized, Double-Blind, Safety, and Efficacy Pilot Study of XXXX Versus XXXXX as First-Line Antihypertensive Therapy in Patients With Type II Diabetes Mellitus and Hypertension

2002-2002; Phase III, A Randomized, Double-Blind, Dose Ranging, Dose Comparison- Controlled Trial to Determine the Safety and Efficacy of an Investigational Study Drug in Subjects with Type II Diabetes

2002-2002; Phase III, A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2 mg TID of XXXXX Over 12 Weeks Followed by a 4-week Re-

## Randomized Treatment Period in Diarrhea-Predominant Irritable Bowel Syndrome Subjects

2001-2002; Phase III, An Open-label, Multinational, Multicenter, Extension Trial to Assess the Long-term Safety and Efficacy of (XXXXX) in Subjects in the XXXXX Clinical Trial Program

2001-2002; Phase III, Randomized, Open-Label, Multicenter Trial of the Safety and Effectiveness of (XXXXX) and XXXXX in Outpatients with Respiratory Tract Infections in Usual Care Settings.

2001-2002; Phase IV, An Open-Label, Multicenter, Single Group Study to Assess the Bacteriological Eradication, Clinical Efficacy and Safety of (XXXXX) Given Once Daily for Five Days in the Treatment of Acute Bacterial Sinusitis (ABS)

2000-2002; A Phase III, Randomized, Placebo Controlled, Double Blinded Trial of (XXXXX) to Repair Hypokalemia and Maintain Serum Potassium in Hypertensive Patients Treated with Diuretic

2001-2002; Phase III, A Multicenter, Double-Blind, Randomized, Placebo-and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of (XXXXX) in Patients with Metabolic Syndrome and Dyslipidemia

2001-2002; Phase IV, A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Flexible Dose Study to Evaluate the Efficacy and Safety of (XXXXX) in Males with Erectile Dysfunction and Congestive Heart Failure

2001-2002; Phase IV, A Randomized, Open Label 16 – Week Study Comparing Breakthrough Bleeding Profiles of Women on XXXXX 1/5 Or XXXXX

2001-2002; Phase III, A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of (XXXXX) vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women

2001-2002 Phase III, A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of (XXXXX) vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Desire) in Postmenopausal Women

2001-2002; Phase III, Study of the efficacy and tolerability of (XXXXX) and twice daily naproxen vs. placebo in the treatment of Hispanic subjects with osteoarthritis of the knee

2001-2002; Phase III, A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing the Percentage of Dyslipidemic Patients Achieving LDL Cholesterol Target with XXXXX Starting Doses of 10 mg, 20 mg, 40 mg, and 80mg

2001-2002; Phase III, Long-Term, Open-Label, Safety and Tolerability Study of XXXXX in Subjects with Primary Hypercholesterolemia

2001-2002; Phase III, XXXXX Cardiovascular Treatment Assessment Versus Enalapril

2001-2001 Phase III, "A Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination XXXXX Therapy in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Half-Maximum to Maximum of the Labeled Doses of Sulfonylurea Monotherapy

2000-2002; A Phase IV, Randomized, Placebo-Controlled, Parallel Group (with Subject Option for the Treatment Switch), Double-Blind Study with Open Label Treatment to Evaluate the Efficacy and Safety of XXXXX in Hispanic Americans with Erectile Dysfunction.

2000-2002; A Phase III, Multicenter, Randomized, Double-Blind, Parallel Group Trial Comparing the Safety and Efficacy of XXXXX to XXXXX as First Line Therapy in Patients with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control with Diet and Exercise

2000-2002; A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of XXXXX Added on to a Background of XXXXX Tablets in /subjects with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control on XXXXX Therapy

2000-2001; A Phase III, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of XXXXX versus Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy.

2000-2001; A Phase III, A Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of XXXXX and XXXXX in the Treatment of Subjects with Hypertension

2000-2000; A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, 9 Week Dose Ranging Study of XXXXX in the Treatment of Mild to Moderate Hypertension

2000-2000; A Phase III, Twenty-Four Week Randomized, Open Label Study of Health Care Resource Use, Quality of Life and Productivity with XXXXX 1mg Twice Daily Versus Traditional Therapy in Females with Irritable Bowel Syndrome Whose Predominant Bowel Symptom is Diarrhea

1999-2002; John A. Hartford Foundation Depression Initiative: IMPACT Study (in seniors)

1999-2002; A Phase III, Double-Blind Efficacy and Safety Study of One Dose of XXXXX (10 mg) Compared to Placebo in Subjects with Primary Hypercholesterolemia

1999-2002; A 24-Week Randomized Double-Blind Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of XXXXX and XXXXX in the Treatment of Subjects With Hypercholesterolemia and Documented Atherosclerosis

1999-2000; A Twenty-Four Week, Randomized, Double-Blind Study of the Effects of XXXXX Versus XXXXX and Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease

1999-2000; A Phase III, Randomized, Double-Blind, Active Control Trial to Evaluate the Safety and Efficacy of a Fixed Combination XXXXX Product in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control on Maximum Dose Sulfonylurea Monotherapy

1999-1999; A Randomized, Double-Blind, Amlodipine and Losartan-Controlled Study of XXXXX in Subjects with Mild to Moderate Hypertension

1998-2002; A Double-Blind, Randomized, Placebo-Controlled Study of XXXXX as Prevention of Cerebrovascular Events in Patients with a Previous Transient Ischemic Attack (TIA) or Stroke

1998-1999; A Study of the Antiproteinuric Effects of XXXXX and Amlodipine in Type II Diabetes with Hypertension and Microalbuminuria or Overt Nephropathy

1998-1999; A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of XXXXX Administered Once or Twice a Day in Patients with Type 2 Diabetes Who have Inadequate Glycemic Control with Diet and Exercise

1998-1999; The Efficacy and Safety of XXXXX Added to Hydrochlorothiazide for the Treatment of Hypertension in Subjects Non-Responsive to Hydrochlorothiazide Alone

1998-1999; A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Elective Titration Study of XXXXX in the Treatment of Mild to Moderate Hypertension

1998-1999; Assessment of Algorithm for Adjunctive Treatment with XXXXX for Weight Loss in Obese Patients in a Large 16-Week, Multicenter, Open-Label Trial in Physician Practice Settings

1998-1999; A Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of XXXXX and Enalapril in the Treatment of Subjects with Severe Hypertension

1998; A Randomized, Double-Blind, Active-and Placebo-Controlled, Parallel Group, Dose Response Study of the Safety, Pharmacokinetics and Effect on Pain and Function of XXXXX in Subjects with Osteoarthritis of the Knee

1998; CONVINCE Protocol for Mild Hypertension

1997; The Safety & Efficacy of Lotrel vs Vasotec in Hypertensive Patients—A Post-Marketing Study

1995; PRAISE-2 (PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION-2). A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Amlodipine on Survival in Patients with Congestive Heart Failure

1992; Insomnia Treatment Study Comparing XXXXX and XXXXX, The Upjohn Company

1992; Evaluation of the Efficacy and Safety of XXXXX Versus XXXXX in Subjects with Non-Insulin Dependent Diabetes Mellitus, The Upjohn Company

1991; Efficacy and Tolerability of Extended-Release (XXXXX) in Adult Patients with Mild to Moderate Uncomplicated Essential Hypertension


1991; Comparison of (XXXXX) and (XXXXX) in the Treatment of Acute Pneumonia in Geriatric Patients, The Upjohn Company

**Other studies conducted (titles not available):**

Gastroparesis  
Osteoarthritis  
Dyspepsia  
Atrial Fibrillation

Lupus  
Diabetes Mellitus  
Hypertension  
Migraine Headaches

Irritable Bowel Syndrome  
Hormone Replacement (patch)  
Hormone Replacement (gel)



2/6/08